Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10715287 | 0.79 | MTNR1A (0.45) | CRBNDDB1SMN1; SMN2 | |
| SCHEMBL29472892 | 0.78 | DDB1 (0.39) | CRBNDDB1ALDH1A1MEN1KMT2A | |
| SCHEMBL29007973 | 0.76 | GABRA1 (0.44) | CRBNDDB1PDCD1CD274 | |
| SCHEMBL29007974 | 0.76 | GABRA1 (0.44) | CRBNDDB1PDCD1CD274 | |
| SCHEMBL6969464 | 0.76 | HSD17B10 (0.40) | CRBNDDB1PDCD1CD274MEN1 | |
| SCHEMBL23978027 | 0.76 | HRH1 (0.39) | KDM4ESMN1; SMN2 | |
| SCHEMBL8270781 | 0.75 | CTSD (0.59) | CRBNDDB1POLBCTSD | |
| SCHEMBL19419777 | 0.75 | CTSD (0.59) | CRBNDDB1POLBCTSD | |
| SCHEMBL2132646 | 0.75 | CTSD (0.59) | CRBNDDB1POLBCTSD | |
| SCHEMBL9771809 | 0.74 | KMT2A (0.40) | CRBNDDB1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912329-B2 | Composition for treatment of tuberculosis | BioVersys AG (CH) | 2014-12-16 | — | — | US | disclosed |
| CN-102458393-B | Composition for treatment of tuberculosis | BIOVERSYS GMBH | 2014-08-20 | — | — | CN | disclosed |
| CN-102458393-A | Composition for treating pulmonary tuberculosis | BIOVERSYS GMBH | 2012-05-16 | — | — | CN | disclosed |
| EP-2445495-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | Bioversys AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BioVersys AG (CH) | 2012-04-26 | — | — | US | disclosed |
| WO-2010149761-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BIOVERSYS GMBH (CH) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | PRMT7, NCOA3, PRMT3 | CRBN 1143/4885DDB1 3948/4885ALDH1A1 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.